Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACUVAIL vs AMMONIUM CHLORIDE IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ketorolac tromethamine, a nonsteroidal anti-inflammatory drug (NSAID), inhibits prostaglandin synthesis by blocking cyclooxygenase (COX-1 and COX-2) enzymes. This reduces ocular inflammation and pain.
Ammonium chloride is an acidifying agent that provides chloride ions and ammonium ions. The ammonium ion is converted to urea in the liver, releasing hydrogen ions, which leads to metabolic acidosis. It also directly stimulates the respiratory center and promotes diuresis by increasing the osmotic load.
Reduction of ocular pain and inflammation following cataract surgery,Treatment of ocular itching associated with seasonal allergic conjunctivitis
Treatment of metabolic alkalosis,Urinary acidification to facilitate excretion of weak bases in poisoning,Hypochloremic states
1 drop in the affected eye 4 times daily.
For metabolic alkalosis: 1-2 g intravenously every 6-12 hours as needed; maximum 6 g/day. For hypochloremic states: 1-2 g orally or intravenously 2-3 times daily.
Terminal elimination half-life is approximately 46 minutes in the aqueous humor following ocular administration in humans.
Terminal elimination half-life is approximately 2-4 hours in adults with normal hepatic and renal function. This reflects the rapid conversion of ammonium to urea in the liver and subsequent renal clearance. Half-life may be prolonged in hepatic or renal impairment.
Primarily hepatic via conjugation with glucuronic acid; minor role of cytochrome P450 enzymes. Approximately 50% is excreted as parent drug and metabolites in urine.
Metabolized primarily in the liver via the urea cycle; ammonium ion is converted to urea, releasing hydrogen ions. The chloride ion is excreted renally.
Primarily renal excretion of metabolites; less than 1% excreted unchanged. Biliary/fecal elimination accounts for <10%.
Renal: >99% as ammonium and chloride ions. The kidney converts ammonia to urea, which is excreted in urine. Fecal and biliary elimination are negligible.
>99% bound to plasma proteins, primarily albumin.
<1% bound to plasma proteins. Ammonium ions are primarily free in plasma.
Intravenous administration in animals suggests Vd ~0.15 L/kg, indicating limited distribution; clinically, it distributes into aqueous humor after topical dosing.
Approximately 0.2-0.3 L/kg, reflecting distribution mainly in extracellular fluid. Ammonium ions do not significantly penetrate cells under normal conditions.
Ocular bioavailability is dependent on formulation; systemic bioavailability after topical ocular administration is extremely low (<1%).
Oral: ~100% absorbed from the gastrointestinal tract, though first-pass hepatic metabolism (urea cycle) limits systemic availability of intact ammonium. Intravenous: 100% bioavailable.
No adjustment required. Drug is minimally systemically absorbed.
Contraindicated in severe renal impairment (GFR <30 m L/min). For GFR 30-50 m L/min: reduce dose by 50% and monitor serum chloride and ammonia. For GFR >50 m L/min: no adjustment necessary.
No adjustment required. Drug is minimally systemically absorbed.
Contraindicated in severe hepatic insufficiency (Child-Pugh class C). For Child-Pugh class B: use with caution, reduce dose by 50% and monitor ammonia levels. For Child-Pugh class A: no adjustment necessary.
Safety and efficacy in pediatric patients have not been established.
For metabolic alkalosis: 50-100 mg/kg intravenously every 6-8 hours; maximum 2 g/day. For hypochloremic states: 75 mg/kg/day orally in divided doses.
No specific dosage adjustment is recommended; use same dose as younger adults.
Start at lower end of dosing range (e.g., 1 g intravenously every 12 hours) due to age-related decline in renal function; monitor serum electrolytes and renal function closely.
No black box warning for ophthalmic use; however, systemic NSAIDs carry risk of serious cardiovascular and gastrointestinal events. Ophthalmic use rarely associated with corneal adverse events.
None
Use with caution in patients with bleeding disorders or those on anticoagulants; may prolong bleeding time. Avoid in patients with known hypersensitivities to NSAIDs or aspirin. Can cause corneal keratopathy; discontinue if corneal epithelial breakdown occurs.
Use with caution in patients with hepatic impairment (risk of ammonia toxicity), renal dysfunction, or respiratory acidosis. Monitor acid-base status, serum chloride, and ammonia levels. Avoid rapid infusion to prevent severe acidosis. Not for use in severe hepatic insufficiency.
Hypersensitivity to any component of the formulation. Active corneal epithelial defect. Patients with aspirin-sensitive asthma.
Severe hepatic insufficiency; severe renal failure with oliguria or anuria; primary respiratory acidosis; hypokalemia (due to risk of exacerbating potassium loss); hypersensitivity to ammonium chloride.
No specific food interactions; systemic absorption is minimal with ophthalmic use. Avoid concurrent use of other NSAID eye drops due to additive irritation.
Avoid excessive dietary intake of chloride-rich foods (e.g., table salt, processed foods) as it may affect treatment. No specific food restrictions, but maintain balanced diet as advised by physician.
Acuvail (ketorolac tromethamine ophthalmic solution) is classified as FDA Pregnancy Category C. Systemic exposure after ocular administration is minimal; however, NSAIDs may cause premature closure of the ductus arteriosus and oligohydramnios in the third trimester. Use during the first and second trimesters should be limited to cases where potential benefit outweighs risk; avoid during the third trimester due to risk of fetal harm.
FDA Pregnancy Category C. Ammonium chloride crosses the placenta. First trimester: insufficient human data; animal studies not available; theoretical risk of fetal acidosis if maternal acidosis induced. Second/third trimester: may cause fetal acidosis, electrolyte disturbances, and potential for fetal harm if maternal overdose or pre-existing acidosis.
Ketorolac is excreted in human milk following systemic administration, but ocular doses produce negligible systemic levels. The M/P ratio is not determined for ophthalmic use. Use with caution in nursing mothers, as the clinical significance is likely low due to minimal systemic absorption.
No human data on excretion in breast milk. M/P ratio unknown. Caution advised; consider risk of infant acidosis and ammonia toxicity if exposed.
No dosage adjustment is required for ophthalmic use during pregnancy, as systemic exposure is negligible. However, avoid use in third trimester due to risks. Pharmacokinetic changes in pregnancy do not significantly alter ocular delivery.
No established dose adjustment for pregnancy. Decreased GI motility and increased plasma volume may alter absorption and distribution; however, dosing should be guided by clinical response and frequent monitoring of acid-base and electrolyte status. Avoid overdosing to prevent maternal and fetal acidosis.
Acuvail (ketorolac tromethamine ophthalmic solution 0.45%) is a nonsteroidal anti-inflammatory drug (NSAID) for ocular use. It is preserved with sodium chloride and not benzalkonium chloride, reducing corneal epithelial toxicity. Administer 1 drop twice daily for ocular pain and inflammation following cataract surgery. Use caution in patients with bleeding tendencies or those on anticoagulants due to risk of increased ocular bleeding. Monitor for corneal epithelial defects and keratitis, especially with prolonged use.
Ammonium chloride is used to treat severe metabolic alkalosis by providing chloride ions and generating mild metabolic acidosis. Monitor serum chloride, bicarbonate, and p H closely during infusion. Avoid in patients with severe hepatic impairment or renal failure. Infusion may cause local irritation; ensure proper IV access.
Wash hands before each use; do not touch tip of bottle to eye or any surface to avoid contamination.,Remove contact lenses before instillation and wait at least 15 minutes before reinserting.,Contact your doctor if you experience eye pain, redness, vision changes, or if symptoms worsen.,Do not use this medication while wearing contact lenses unless directed by your doctor.,Store at room temperature, keep bottle tightly closed when not in use, and discard within 28 days of opening.
This medication is used to correct an acid-base imbalance in your blood.,It will be given intravenously (IV) by a healthcare professional.,Report any burning, pain, or redness at the IV site immediately.,Do not consume large amounts of salt or salty foods unless directed.,Tell your doctor if you have liver or kidney disease.
No interactions on record
"Ammonium chloride, an acidifying agent, reduces urinary pH, which increases the renal clearance of lisdexamfetamine and its active metabolite d-amphetamine. This accelerated elimination leads to decreased systemic exposure and potentially diminished therapeutic efficacy of lisdexamfetamine. Clinically, patients may experience reduced symptom control for ADHD or binge eating disorder, requiring dose adjustments or alternative therapies."
"Sufentanil, a potent opioid analgesic, may increase renal excretion of ammonium chloride by promoting diuresis through opioid-induced release of antidiuretic hormone (ADH) and subsequent water reabsorption, leading to dilutional acidosis and enhanced ammonium excretion. This interaction can result in reduced serum ammonium levels and decreased efficacy of ammonium chloride as an acidifying agent, potentially compromising its therapeutic effect in metabolic alkalosis or urinary tract infections. Clinical outcomes may include incomplete correction of metabolic alkalosis or reduced antimicrobial activity of ammonium chloride in the urine."
"Ammonium chloride acidifies the urine, which increases the renal excretion of amphetamine by favoring its ionized form in the tubular lumen, thereby reducing its reabsorption. This leads to a decreased serum concentration of amphetamine and potentially diminished therapeutic efficacy. Clinically, patients may experience reduced mood-elevating or stimulant effects, requiring dose adjustment."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACUVAIL vs AMMONIUM CHLORIDE IN PLASTIC CONTAINER, answered by our medical review team.
ACUVAIL is a NSAID Ophthalmic that works by Ketorolac tromethamine, a nonsteroidal anti-inflammatory drug (NSAID), inhibits prostaglandin synthesis by blocking cyclooxygenase (COX-1 and COX-2) enzymes. This reduces ocular inflammation and pain.. AMMONIUM CHLORIDE IN PLASTIC CONTAINER is a Expectorant/Systemic Acidifier that works by Ammonium chloride is an acidifying agent that provides chloride ions and ammonium ions. The ammonium ion is converted to urea in the liver, releasing hydrogen ions, which leads to metabolic acidosis. It also directly stimulates the respiratory center and promotes diuresis by increasing the osmotic load.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACUVAIL and AMMONIUM CHLORIDE IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACUVAIL is: 1 drop in the affected eye 4 times daily.. The standard adult dose of AMMONIUM CHLORIDE IN PLASTIC CONTAINER is: For metabolic alkalosis: 1-2 g intravenously every 6-12 hours as needed; maximum 6 g/day. For hypochloremic states: 1-2 g orally or intravenously 2-3 times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACUVAIL and AMMONIUM CHLORIDE IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACUVAIL is classified as Category C. Acuvail (ketorolac tromethamine ophthalmic solution) is classified as FDA Pregnancy Category C. Systemic exposure after ocular administration is minimal; however, NSAIDs may cause . AMMONIUM CHLORIDE IN PLASTIC CONTAINER is classified as Category C. FDA Pregnancy Category C. Ammonium chloride crosses the placenta. First trimester: insufficient human data; animal studies not available; theoretical risk of fetal acidosis if mate. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.